Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Drug Delivery to CNS Technologies, Markets and Companies |
Jan 2012 | £1,945 | 100% |
| CNS Drug Discoveries: Schizophrenia Chapter | Aug 2008 | £595 | 93% |
| Parkinson's Disease – Pipeline Assessment and Market Forecasts to 2016 | Jun 2010 | £1,265 | 92% |
| Alzheimer's Disease Pipeline Assessment and Market Forecasts to 2017 |
Nov 2010 | £1,265 | 91% |
| Migraine Therapeutics Pipeline Assessment and Market Forecasts to 2016 |
Jul 2010 | £1,265 | 90% |
| Acute Ischemic Stroke Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Dec 2010 | £1,265 | 89% |
| Drug Discovery and Preclinical Molecules by Therapy Area Innovation Focuses on Stem Cell Therapies and Gene Therapies |
Feb 2011 | £2,215 | 88% |
| Epilepsy Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 87% |
| Innovations in Medical Imaging Technological Advances, Growth Opportunities and Future Market Outlook |
Aug 2009 | £2,425 | 86% |
| Postherpetic Neuralgia (PHN) Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Jun 2011 | £1,265 | 85% |
| Dementia Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 85% |
| Protease Inhibitors Innovation Drives Drug Pipeline |
Feb 2009 | £2,370 | 84% |
| Diabetic Neuropathy Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 84% |
| Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family Sales & Marketing |
Oct 2007 | £4,805 | 84% |
| Stem Cell-Based Therapeutic Delivery Challenges & Opportunities |
Dec 2008 | £945 | 83% |
| CNS Therapeutics | May 2008 | £2,500 | 83% |
| Delivering Opportunities in the Inhalable Drugs Market Innovative formulations and devices |
Feb 2010 | £2,425 | 83% |
| CNS Drug Discoveries: what the future holds | Aug 2008 | £1,795 | 81% |
| Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
Oct 2006 | £7,210 | 81% |
| Acute Ischemic Stroke (AIS) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Sep 2011 | £2,215 | 80% |
| Amyotrophic Lateral Sclerosis (ALS) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Sep 2011 | £2,215 | 80% |
| M&A trends in Pharma | Oct 2008 | £7,210 | 79% |
| Cell therapy (2 parts) Technologies, Markets and Companies |
Jan 2012 | £3,560 | 79% |
| Fibromyalgia Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 79% |
| UCB: Pipeline - Products - Performance - Potential | Jan 2010 | £595 | 79% |
| Pain Therapeutics Technologies, Markets and Companies |
Jan 2012 | £2,590 | 79% |
| Biomarkers: Applications and trends that are revolutionising drug discovery and development | Aug 2010 | £695 | 78% |
| Advances in Imaging Biomarkers Innovative technologies, applications in R&D and clinical practice, and informatics and regulatory requirements |
Jul 2010 | £2,425 | 78% |
| Multiple Sclerosis Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Dec 2010 | £1,265 | 78% |
| U.S. CRO Markets - Key Therapeutic Areas | Jul 2009 | £3,795 | 78% |
